Moderna Stock News

SINGAPORE: Vaccine maker Moderna on Tuesday (Feb 15) announced plans to set up a new subsidiary in Singapore, as well as three others in Malaysia, Taiwan and Hong Kong . The new subsidiary will provide local presence to support the delivery of mRNA vaccines and therapeutics in Singapore, the company said i

A biotechnology company in Cape Town announced this month that it had succeeded in producing its own mRNA vaccine, but health experts are concerned the project will be blocked by Moderna’s patents

The Nasdaq-listed biotechnology company plans to initially hire about 1,000 people in the city, with its new office possibly serving as a gateway to mainland China in the long term, Stephane Bancel, its global CEO, said in an interview.

Moderna, the United States pharmaceutical specialist in RNA therapeutics and mRNA vaccines, said it would open a branch in Hong Kong, adding to its commercial presence in Asia to tap the region’s health care market.The company, based in Cambridge in the US state of Massachusetts, plans to hire about 1,000 people initially in Hong Kong, using the city as the gateway to mainland China, according to its chief executive officer Stephane Bancel.“Asia is a very important region, [and] it has the most…

David Einhorn enjoyed a strong fourth quarter as his hedge fund Greenlight Capital outperformed the S&P 500''s 11% gain by returning 18.6%, according to the billionaire investor''s latest 13F filing.

In the middle of last year, The U.S. Food and Drug Administration (FDA) added a warning about the risk of developing heart inflammation to information about the Moderna and Pfizer COVID-19 vaccines. Then on November 5, 2021, the Centers for […] The post Two teenage boys ‘suddenly and unexpectedly died in their sleep’ following the second dose of mRNA Covid vaccines, autopsy findings from College of American Pathologists show appeared first on Tech News | Startups News .

Moderna’s COVID-19 Vaccine Finally Fully Approved by FDA – The U.S. Food and Drug Administration granted full approval to Moderna’s COVID-19 vaccine Monday, a little more than one year after the vaccine was made available under an emergency use authorization. The FDA only grants full approval after it has had enough time to gather sufficient […]

The post Losses Top $140 Billion As Insiders Sell Millions Of Dollars In Shares appeared on BitcoinEthereumNews.com . Topline Shares of Moderna plummeted Monday as Covid-19 vaccine-makers led a turbulent market decline, pushing the stock to its lowest level in nearly a year after disappointing study results and…

Moderna (MRNA) closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday

Moderna Inc. (NASDAQ: MRNA ) shares are trading lower Monday. A recent CDC study showed protection from COVID-19 booster doses can wane after four months. Moderna investors are also expressing concerns about recent stock sales from Moderna CEO Stéphane Bancel , as well as the deletion of his Twitter account. Moderna was down 12.27% at $141.52 Monday afternoon. See Related: Moderna CEO Sells Shares, Deletes Social Media: What You Need To Know Moderna Daily Chart Analysis Over the past few weeks the stock has seen strong downward movement and has pushed support in what traders call an ascending triangle pattern. This is showing Full story available on Benzinga.com

COVID-19 vaccine boosters from Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ) become less effective after four months but still provide significant protection against hospitalization, a CDC study found. While vaccine efficacy was still strong two months after a booster shot, it declined significantly after four months. Efficacy against COVID-19associated emergency department visits and Full story available on Benzinga.com

Moderna Inc (NASDAQ: MRNA ) shares are down more than 40% since the start of the year and continue to trend lower Monday. Vaccine stocks are facing selling pressure as the COVID-19 omicron variant fades, but Moderna investors have been expressing concerns about recent stock sales from Moderna CEO Stéphane Bancel , as well as the presumed deletion of his Twitter account. CNBC reporter Meg Tirrell said she reached out to Bancel Monday and Full story available on Benzinga.com

The stock made an attempt to settle below the $140 level.

A delay for Pfizer and BioNTech appears to be weighing on all vaccine stocks.